RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+9.05%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$661M
AUM Growth
+$661M
(+5.4%)
Cap. Flow
-$14.7M
Cap. Flow
% of AUM
-2.23%
Top 10 Holdings %
Top 10 Hldgs %
25.72%
Holding
101
New
10
Increased
24
Reduced
44
Closed
5
Top Buys
| 1 |
ABMD
Abiomed Inc
ABMD
|
$13M |
| 2 |
Perrigo
PRGO
|
$11.6M |
| 3 |
WBA
Walgreens Boots Alliance
WBA
|
$11.2M |
| 4 |
CVS Health
CVS
|
$8.12M |
| 5 |
Bausch Health
BHC
|
$7.01M |
Top Sells
| 1 |
Amgen
AMGN
|
$8.6M |
| 2 |
Alkermes
ALKS
|
$7.7M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$6.17M |
| 4 |
Edwards Lifesciences
EW
|
$5.92M |
| 5 |
HCA Healthcare
HCA
|
$5.68M |
Sector Composition
| 1 | Healthcare | 92.69% |
| 2 | Financials | 1.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
STJ
26
DELISTED
St Jude Medical
STJ
| $10.8M | 1.63% |
175,000
-15,000
| -8% | -$927K |
|
27
Becton Dickinson
BDX
$54.3B
| $10.6M | 1.61% |
70,725
-22,550
| -24% | -$3.39M |
|
28
Labcorp
LH
$22.8B
| $10M | 1.51% |
94,284
| – | – |
|
29
Centene
CNC
$14.8B
| $9.81M | 1.48% |
298,000
-52,000
| -15% | -$1.71M |
|
30
Nektar Therapeutics
NKTR
$543M
| $9.79M | 1.48% |
38,733
-7,134
| -16% | -$1.8M |
|
31
Cardinal Health
CAH
$36B
| $9.28M | 1.4% |
104,000
-55,000
| -35% | -$4.91M |
|
32
DexCom
DXCM
$30.9B
| $8.6M | 1.3% |
420,000
+84,000
| +25% | +$1.72M |
|
|
HNT
33
DELISTED
HEALTH NET INC
HNT
| $8.35M | 1.26% |
122,000
-28,000
| -19% | -$1.92M |
|
|
MDVN
34
DELISTED
MEDIVATION, INC.
MDVN
| $7.73M | 1.17% |
160,000
+46,000
| +40% | +$2.22M |
|
35
Halozyme
HALO
$8.75B
| $7.11M | 1.07% |
410,000
+238,000
| +138% | +$4.12M |
|
|
ENDP
36
DELISTED
Endo International plc
ENDP
| $7.1M | 1.07% |
116,000
+43,000
| +59% | +$2.63M |
|
|
37
Vertex Pharmaceuticals
VRTX
$102B
| $7.05M | 1.07% |
56,000
-49,000
| -47% | -$6.17M |
|
|
CEMP
38
DELISTED
Cempra, Inc.
CEMP
| $7.04M | 1.06% |
226,000
-72,000
| -24% | -$2.24M |
|
|
39
Bausch Health
BHC
$2.72B
| $7.01M | 1.06% |
+69,000
| New | +$7.01M |
|
|
ITCI
40
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.78M | 1.02% |
126,000
-39,000
| -24% | -$2.1M |
|
|
41
HCA Healthcare
HCA
$95.4B
| $6.49M | 0.98% |
96,000
-84,000
| -47% | -$5.68M |
|
|
ESRX
42
DELISTED
Express Scripts Holding Company
ESRX
| $6.47M | 0.98% |
74,000
-22,000
| -23% | -$1.92M |
|
|
KERX
43
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $6.23M | 0.94% |
1,233,000
-330,000
| -21% | -$1.67M |
|
|
RVNC
44
DELISTED
Revance Therapeutics, Inc.
RVNC
| $5.91M | 0.89% |
173,000
+25,000
| +17% | +$854K |
|
45
Jazz Pharmaceuticals
JAZZ
$7.99B
| $5.9M | 0.89% |
42,000
-4,700
| -10% | -$661K |
|
46
Alnylam Pharmaceuticals
ALNY
$58.6B
| $5.84M | 0.88% |
62,000
-14,000
| -18% | -$1.32M |
|
|
RAD
47
DELISTED
Rite Aid Corporation
RAD
| $5.32M | 0.8% |
33,900
+650
| +2% | +$102K |
|
48
Universal Health Services
UHS
$11.6B
| $5.26M | 0.8% |
44,000
-4,900
| -10% | -$586K |
|
49
Boston Scientific
BSX
$159B
| $5.05M | 0.76% |
+274,000
| New | +$5.05M |
|
50
Celldex Therapeutics
CLDX
$1.57B
| $5.02M | 0.76% |
21,333
+1,666
| +8% | +$392K |
|